Nemera: Drug delivery devices

Nemera cancels presence at global events until 2021
At Nemera, our people's safety is a top priority and we believe it's our duty to contain the spread of the virus to protect those around us.
Stay connected digitally
Nemera’s takes dermal treatments to millions of patients
Bioscience Today’s latest issue features Nemera’s article on how we strike the perfect balance of ensuring safety of our dermal drug delivery devices whilst fulfilling regulatory requirements and patient needs. Read more from our Category Managers Audre
Read the full article
Nemera and Noble announce collaboration to support patients who self-administer medication
Nemera is excited to leverage the new collaboration to expand end-to-end offering of the parenteral franchise and increase patient onboarding through safer multi-use training devices
Read the full press release

Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generic industries

We leverage a long standing experience to provide you leading-edge drug delivery devices
for different application areas, from design to large scale manufacturing.

Nemera acquired Insight Product Development and integrates it in its new Insight Innovation Center
Learn more

Device design & development

World Class Innovation Center: we are passionate to develop the best solutions
Learn more

100% quality focused manufacturing

Global GMP manufacturing capabilities and strong continuous improvement culture
Learn more

A wide range of drug delivery devices for every application

Ophthalmic Preservative-free multidose eye dropper
Ophthalmic
Nasal spray bioequivalence
Ear, Nose, Throat
Passive safety system for prefilled syringes
Parenteral
Airless dispenser for dermal topical delivery
Dermal
Inhaler for astham and COPD
Inhalation

Our last news

Contact us

E-mail: information@nemera.net

This form collects your name and email so that we can send you your requested content. Check out our legal notices for more details.

Linkedin-in Twitter Youtube